Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses

Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses

As the global COVID-19 pandemic continues and new SARS-CoV-2 variants of concern emerge, vaccines remain an important tool for preventing the pandemic. The inactivated or subunit vaccines themselves generally exhibit low immunogenicity, which needs adjuvants to improve the immune response. We previo...

Full description

Bibliographic Details
Main Authors: Yidan Qiao, Yikang Zhan, Yongli Zhang, Jieyi Deng, Achun Chen, Bingfeng Liu, Yiwen Zhang, Ting Pan, Wangjian Zhang, Hui Zhang, Xin He
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
nanoparticle vaccine
adjuvant
tuberculosis vaccine
TLR2 agonist
Pam2CSK4
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.992062/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.992062/full

Similar Items